Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Pharmalot Returns

    I’m glad to report that Ed Silverman has revived the Pharmalot blog, now at the Wall Street Journal. This is the third iteration, and I’m glad to see that it’s as unkillable as it appears to be! Read More
  • Business and Markets

    How to Buy, Buy, Buy

    I really got a kick out of “The Seven Deadly Sins of Biotech Investing“, sent to Adam Feuerstein by one of his readers. It’s a sort of Screwtape Letters/Devil’s Dictionary look at the sector, with gems of wisdom like this: Find a good Internet message board to discuss how great an investment the biotech stock… Read More
  • Business and Markets

    AstraZeneca Survives

    So Pfizer has officially called off their quest to acquire AstraZeneca. I didn’t expect things to end like this – up until now, what Pfizer has wanted, Pfizer has gotten (well, except in the clinic). There may well have been other behind-the-scenes overtures that we never heard about being rejected over the years, but this… Read More
  • Business and Markets

    Two Looks At Drug Industry Productivity

    Matthew Herper has a really interesting story in Forbes on a new report that attempts to rank biopharma companies by their R&D abilities. Richard Evans of Sector and Sovereign Health (ex-Roche) has ranked companies not on their number of drugs, but on their early-stage innovation. He counts patents, for example, but not the later ones… Read More
  • Business and Markets

    The Biggest Chemistry Employers – Guess

    According to Bruce Booth on Twitter, the largest single employer of R&D chemists in the world is now WuXi. They have >2500. And the number two company is their direct competitor ChemPartner, with 1300. Someone get in the time machine, fly back to about 1990, and try those figures out on them. Read More
  • Business and Markets

    Pfizer/AstraZeneca: The Arm-Wrestling Phase

    Don’t forget – you can bet that the people at AstraZeneca aren’t forgetting – that Pfizer still has until May 26th under UK securities law for their takeover offer. Today’s Wall Street Journal reports that some institutional investors are pressuring AZ’s board to accept the offer (or at least open negotiations),… Read More
  • Business and Markets

    Perhaps Not Quite Technically Legal, Come to Think of It

    Now, wait – you’re telling me that just because you’re a doctor involved in the clinical trial of a small company’s main drug, and you’ve found out that the trial has been halted by the FDA. . .you’re saying that you can’t actually unload all your stock on that information before the public announcement? Wh… Read More
  • Business and Markets

    AstraZeneca Says No Again

    Now what? Pfizer has upped its offer for AstraZeneca yet again, and up to the figure that they seem to have calculated would bring them to the negotiating table. But AZ has told them to buzz off yet again, sending their own shares down hard. That’s because Pfizer also stated that they would not launch… Read More
  • Business and Markets

    China Raises the Stakes in the GSK Scandal

    GSK’s troubles in China have just gotten even more serious. The government has formally charged Mark Reilly, former head of the company’s operations in China, of organizing and participating in a bribery scheme. This seems to have been a stronger step than people were expecting – we’ll see what happens. Reilly’s wherea… Read More
  • Business and Markets

    Pfizer’s Shareholders and AstraZeneca’s

    The Financial Times is out with an editorial denouncing Pfizer’s attempted takeover of AstraZeneca. It’s definitely worth a read for the case it makes. What’s a drug company supposed to be doing, anyway? But (the effect on British research) is not the only big question requiring discussion. Another is the extent to which the board… Read More
...303132...